Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three ...

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver ...

DelveInsight’s, “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

Research Antibodies Market. The global research antibodies market is on a trajectory of significant expansion, driven by the ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...

It is composed of the antibody binding fragment (Fab) of humanized monoclonal antibody against TNF conjugated to polyethylene glycol; therefore, unlike other agents, it does not contain the ...